



Keystone 65 Rx HMO
Personal Choice 65SM Rx PPO
Select Option[®] Rx PDP

2022 Utilization Management Criteria: Step Therapy

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN**

This document was updated on 12/5/2022. For more recent information or other questions, please contact our Member Help Team: Keystone 65 at 1-844-352-1699, Personal Choice 65 at 1-888-879-4293, Select Option at 1-888-678-7009 or, for TTY/TDD users, 711, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit www.ibxmedicare.com to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means Independence Blue Cross. When it refers to “plan” or “our plan,” it means Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2023, and from time to time during the year.

Independence Blue Cross offers Medicare Advantage plans with a Medicare contract. Enrollment in Independence Medicare Advantage plans depends on contract renewal.

Keystone 65: Benefits underwritten by Keystone Health Plan East, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

Personal Choice 65 and Select Option: Benefits underwritten by QCC Insurance Company, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this “utilization management.” These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug. Drugs that require prior authorization are listed in *2022 Utilization Management Criteria: Prior Authorization*.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require step therapy are listed in this document.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have quantity limits are listed in the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting www.ibxmedicare.com.

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

How to use this document

This document, along with *2022 Utilization Management Criteria: Prior Authorization*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note “ST” in the “Requirements” column of the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 35. The restriction information includes step therapy criteria.

Be sure to read all the information listed for your affected drug. If you have any questions or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 at 1-844-352-1699, Personal Choice 65 at 1-888-879-4293, Select Option at 1-888-678-7009.

ALBUTEROL 2022

Products Affected

- PROAIR DIGIHALER AEROSOL POWDER
BREATH ACTIVATED 108 (90 BASE) MCG/ACT
INHALATION

Details

| | |
|-----------------|---|
| Criteria | Trial of Proair Respiclick. Always Applies. |
|-----------------|---|

ANTIDEPRESSANTS [SNRIS] 2022

Products Affected

- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of two generic formulary serotonin-norepinephrine reuptake Inhibitor (SNRI). Applies to new starts. |
|-----------------|---|

BENZODIAZEPINES 2022

Products Affected

- ATIVAN TABLET 0.5 MG ORAL
- ATIVAN TABLET 1 MG ORAL
- ATIVAN TABLET 2 MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of two generic formulary benzodiazepines. Always Applies. |
|-----------------|---|

BRAND ANTIPSYCHOTICS 2022

Products Affected

- ABILIFY TABLET 10 MG ORAL
- ABILIFY TABLET 15 MG ORAL
- ABILIFY TABLET 2 MG ORAL
- ABILIFY TABLET 20 MG ORAL
- ABILIFY TABLET 30 MG ORAL
- ABILIFY TABLET 5 MG ORAL
- CAPLYTA CAPSULE 10.5 MG ORAL
- CAPLYTA CAPSULE 21 MG ORAL
- CAPLYTA CAPSULE 42 MG ORAL
- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- REXULTI TABLET 0.25 MG ORAL
- REXULTI TABLET 0.5 MG ORAL
- REXULTI TABLET 1 MG ORAL
- REXULTI TABLET 2 MG ORAL
- REXULTI TABLET 3 MG ORAL
- REXULTI TABLET 4 MG ORAL
- SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL
- SAPHRIS TABLET SUBLINGUAL 2.5 MG SUBLINGUAL
- SAPHRIS TABLET SUBLINGUAL 5 MG SUBLINGUAL
- SECUADO PATCH 24 HOUR 3.8 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 5.7 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 7.6 MG/24HR TRANSDERMAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL

Details

| Criteria | |
|----------|---|
| | Trial of two generic antipsychotic products. Applies to new starts. |

BRAND BUPROPION PRODUCTS 2022

Products Affected

- APLENZIN TABLET EXTENDED RELEASE 24 HOUR 174 MG ORAL
- APLENZIN TABLET EXTENDED RELEASE 24 HOUR 348 MG ORAL
- APLENZIN TABLET EXTENDED RELEASE 24 HOUR 522 MG ORAL
- FORFIVO XL TABLET EXTENDED RELEASE 24 HOUR 450 MG ORAL
- WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 150 MG ORAL
- WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 300 MG ORAL

Details

| | |
|-----------------|--|
| Criteria | Trial of one generic formulary bupropion product. Applies to new starts. |
|-----------------|--|

BRAND ORAL NSAIDS 2022

Products Affected

- ELYXYB SOLUTION 120 MG/4.8ML ORAL
- LOFENA TABLET 25 MG ORAL
- RELAFEN DS TABLET 1000 MG ORAL

Details

| | |
|-----------------|--|
| Criteria | Trial of two generic formulary non-steroidal anti-inflammatory drugs (NSAIDs). Always applies. |
|-----------------|--|

BUDESONIDE CAPSULES 2022

Products Affected

- ORTIKOS CAPSULE EXTENDED RELEASE 24 HOUR 6 MG ORAL
- ORTIKOS CAPSULE EXTENDED RELEASE 24 HOUR 9 MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of generic budesonide capsule DR 3mg (generic Entocort EC). Always applies. |
|-----------------|---|

CITALOPRAM CAPSULE 2022

Products Affected

- *citalopram hydrobromide capsule 30 mg oral*

Details

| | |
|-----------------|---|
| Criteria | Trial of both generic formulary citalopram oral solution and tablet. Applies to new starts. |
|-----------------|---|

CUPRIMINE 2022

Products Affected

- CUPRIMINE CAPSULE 250 MG ORAL

Details

| | |
|-----------------|--|
| Criteria | Trial of penicillamine or brand Depen. Always applies. |
|-----------------|--|

DRIZALMA 2022

Products Affected

- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 20 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 30 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 40 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 60 MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of generic formulary duloxetine. Applies to new starts. |
|-----------------|---|

DYMISTA 2022

Products Affected

- *azelastine-fluticasone suspension 137-50 mcg/act nasal*

Details

| | |
|-----------------|---|
| Criteria | Trial of both generic fluticasone nasal spray and azelastine nasal spray. Always applies. |
|-----------------|---|

EPRONTIA 2022

Products Affected

- EPRONTIA SOLUTION 25 MG/ML ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of generic topiramate. Applies to new starts. |
|-----------------|---|

GIMOTI 2022

Products Affected

- GIMOTI SOLUTION 15 MG/ACT NASAL

Details

| | |
|-----------------|---|
| Criteria | Trial of generic oral metoclopramide. Always applies. |
|-----------------|---|

GOUT AGENTS 2022

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

| | |
|-----------------|---|
| Criteria | Trial of generic allopurinol. Always applies. |
|-----------------|---|

IMPETIGO AGENTS 2022

Products Affected

- ALTABAX OINTMENT 1 % EXTERNAL

Details

| | |
|-----------------|---|
| Criteria | Trial of generic formulary mupirocin ointment. Always applies |
|-----------------|---|

INSULIN GLARGINE 2022

Products Affected

- BASAGLAR KWIKPEN SOLUTION PEN-INJECTOR
100 UNIT/ML SUBCUTANEOUS

Details

| Criteria | Trial of two of the following: Lantus, Levemir, Toujeo, Tresiba. Always applies. |
|----------|--|
|----------|--|

LONHALA STEP THERAPY 2022

Products Affected

- LONHALA MAGNAIR REFILL KIT SOLUTION 25 MCG/ML INHALATION

Details

| | |
|-----------------|--|
| Criteria | Trial of Spiriva or Spiriva Respimat or Incruse Ellipta. Always applies. |
|-----------------|--|

MIGRAINE AGENTS 2022

Products Affected

- NURTEC TABLET DISPERSIBLE 75 MG ORAL
- TOSYMRA SOLUTION 10 MG/ACT NASAL

Details

| | |
|-----------------|--|
| Criteria | Trial of one generic formulary triptans, or any two of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline (e)SNRI antidepressants: venlafaxine (ER). Or any combination of the above. Always applies. |
|-----------------|--|

MULTIPLE SCLEROSIS AGENTS 2022

Products Affected

- BAFIERTAM CAPSULE DELAYED RELEASE 95 MG ORAL
- COPAXONE SOLUTION PREFILLED SYRINGE 20 MG/ML SUBCUTANEOUS
- COPAXONE SOLUTION PREFILLED SYRINGE 40 MG/ML SUBCUTANEOUS
- KESIMPTA SOLUTION AUTO-INJECTOR 20 MG/0.4ML SUBCUTANEOUS
- MAVENCLAD (10 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAVENCLAD (4 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAVENCLAD (5 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAVENCLAD (6 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAVENCLAD (7 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAVENCLAD (8 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAVENCLAD (9 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAYZENT STARTER PACK TABLET THERAPY PACK 0.25 MG ORAL
- MAYZENT STARTER PACK TABLET THERAPY PACK 12 X 0.25 MG ORAL
- MAYZENT TABLET 0.25 MG ORAL
- MAYZENT TABLET 1 MG ORAL
- MAYZENT TABLET 2 MG ORAL
- PONVORY STARTER PACK TABLET THERAPY PACK 2-3-4-5-6-7-8-9 & 10 MG ORAL
- PONVORY TABLET 20 MG ORAL
- VUMERITY CAPSULE DELAYED RELEASE 231 MG ORAL
- ZEPOSIA 7-DAY STARTER PACK CAPSULE THERAPY PACK 4 X 0.23MG & 3 X 0.46MG ORAL
- ZEPOSIA CAPSULE 0.92 MG ORAL
- ZEPOSIA STARTER KIT CAPSULE THERAPY PACK 0.23MG & 0.46MG & 0.92MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of two of the following medications: (1) Avonex (interferon beta-1a), (2) Plegridy (peginterferon beta-1a), (3) Betaseron (interferon beta-1b), (4) Glatopa (glatiramer acetate), (5) Tecfidera (Dimethyl Fumarate), (6) Gilenya (fingolimod), (7) Aubagio (teriflunomide), or (8) Rebif (interferon beta 1a). Or trial of two of the following medications: (1) Humira(adalimumab), and (2) Xeljanz/Xeljanz XR (Tofacitinib). Applies to new starts. |
|-----------------|---|

OIC AGENTS 2022

Products Affected

- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS
- RELISTOR SOLUTION 8 MG/0.4ML SUBCUTANEOUS
- RELISTOR TABLET 150 MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of Amitiza (lubiprostone) or lactulose. Always Applies. |
|-----------------|---|

OPHTHALMIC PROSTAGLANDINS 2022

Products Affected

- RHOPRESSA SOLUTION 0.02 % OPTHALMIC

Details

| | |
|-----------------|--|
| Criteria | Trial of two from the following: generic formulary ophthalmic prostaglandin products, brand Lumigan 0.01%. Always applies. |
|-----------------|--|

PROTON PUMP INHIBITORS (PPIs) 2022

Products Affected

- *omeprazole-sodium bicarbonate packet 20-1680 mg oral*
- *omeprazole-sodium bicarbonate packet 40-1680 mg oral*
- *rabeprazole sodium tablet delayed release 20 mg oral*

Details

| | |
|-----------------|--|
| Criteria | Trial of two generic formulary proton pump inhibitors. Always applies. |
|-----------------|--|

RELTONE 2022

Products Affected

- RELTONE CAPSULE 200 MG ORAL
- RELTONE CAPSULE 400 MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of generic formulary ursodiol capsules. Always applies. |
|-----------------|---|

SANCUSO 2022

Products Affected

- SANCUSO PATCH 3.1 MG/24HR TRANSDERMAL

Details

| | |
|-----------------|---|
| Criteria | Trial of (a) ondansetron or granisetron and (b) aprepitant. Always applies. |
|-----------------|---|

SAVELLA 2022

Products Affected

- SAVELLA TABLET 100 MG ORAL
- SAVELLA TABLET 12.5 MG ORAL
- SAVELLA TABLET 25 MG ORAL
- SAVELLA TABLET 50 MG ORAL
- SAVELLA TITRATION PACK 12.5 & 25 & 50 MG ORAL

Details

| | |
|-----------------|---|
| Criteria | Trial of generic formulary duloxetine. Applies to new starts. |
|-----------------|---|

SERTRALINE CAPSULE 2022

Products Affected

- *sertraline hcl capsule 150 mg oral*
- *sertraline hcl capsule 200 mg oral*

Details

| | |
|-----------------|---|
| Criteria | Trial of TWO of the following medications: (1) citalopram (oral solution/tablet) (2) escitalopram (3) fluoxetine (4) fluvoxamine (5) paroxetine, OR (6) sertraline (concentrate/tablet). Applies to new starts. |
|-----------------|---|

TRULANCE 2022

Products Affected

- TRULANCE TABLET 3 MG ORAL

Details

| | |
|-----------------|--|
| Criteria | Trial of both of the following: (1) lactulose and (2) Linzess or Amitiza (lubiprostone). Always applies. |
|-----------------|--|

UBRELVY 2022

Products Affected

- UBRELVY TABLET 100 MG ORAL
- UBRELVY TABLET 50 MG ORAL

Details

| | |
|-----------------|--|
| Criteria | Trial of one generic formulary triptans. Always applies. |
|-----------------|--|

VENLAFAXINE BESYLATE TAB ER 2022

Products Affected

- *venlafaxine besylate er tablet extended release 24 hour 112.5 mg oral*

Details

| | |
|-----------------|--|
| Criteria | Trial of both generic formulary venlafaxine hydrochloride extended-release tablet and capsule before receiving Venlafaxine Besylate extended-release tablet. Applies to new starts only. |
|-----------------|--|

VIIBRYD 2022

Products Affected

- VIIBRYD STARTER PACK KIT 10 & 20 MG ORAL
- VIIBRYD TABLET 10 MG ORAL
- VIIBRYD TABLET 20 MG ORAL
- VIIBRYD TABLET 40 MG ORAL

Details

| | |
|-----------------|--|
| Criteria | Trial of two generic formulary selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. Applies to new starts. |
|-----------------|--|

XCOPRI 2022

Products Affected

- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL
- XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL
- XCOPRI TABLET 100 MG ORAL
- XCOPRI TABLET 150 MG ORAL
- XCOPRI TABLET 200 MG ORAL
- XCOPRI TABLET 50 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X 200 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X 100 MG ORAL

Details

| | |
|-----------------|--|
| Criteria | Trial of two generic formulary anticonvulsants. Applies to new starts. |
|-----------------|--|

Index

| | | | |
|---|----|---|----|
| ABILIFY TABLET 10 MG ORAL..... | 6 | FANAPT TABLET 6 MG ORAL..... | 6 |
| ABILIFY TABLET 15 MG ORAL..... | 6 | FANAPT TABLET 8 MG ORAL..... | 6 |
| ABILIFY TABLET 2 MG ORAL..... | 6 | FANAPT TITRATION PACK TABLET 1 & 2 & 4 | |
| ABILIFY TABLET 20 MG ORAL..... | 6 | & 6 MG ORAL..... | 6 |
| ABILIFY TABLET 30 MG ORAL..... | 6 | <i>febuxostat tablet 40 mg oral</i> | 16 |
| ABILIFY TABLET 5 MG ORAL..... | 6 | <i>febuxostat tablet 80 mg oral</i> | 16 |
| ALTABAX OINTMENT 1 % EXTERNAL..... | 17 | FETZIMA CAPSULE EXTENDED RELEASE 24 | |
| APLENZIN TABLET EXTENDED RELEASE 24 | | HOUR 120 MG ORAL..... | 4 |
| HOUR 174 MG ORAL..... | 7 | FETZIMA CAPSULE EXTENDED RELEASE 24 | |
| APLENZIN TABLET EXTENDED RELEASE 24 | | HOUR 20 MG ORAL..... | 4 |
| HOUR 348 MG ORAL..... | 7 | FETZIMA CAPSULE EXTENDED RELEASE 24 | |
| APLENZIN TABLET EXTENDED RELEASE 24 | | HOUR 40 MG ORAL..... | 4 |
| HOUR 522 MG ORAL..... | 7 | FETZIMA CAPSULE EXTENDED RELEASE 24 | |
| ATIVAN TABLET 0.5 MG ORAL..... | 5 | HOUR 80 MG ORAL..... | 4 |
| ATIVAN TABLET 1 MG ORAL..... | 5 | FETZIMA TITRATION CAPSULE ER 24 HOUR | |
| ATIVAN TABLET 2 MG ORAL..... | 5 | THERAPY PACK 20 & 40 MG ORAL..... | 4 |
| <i>azelastine-fluticasone suspension 137-50</i> | | FORFIVO XL TABLET EXTENDED RELEASE 24 | |
| <i>mcg/act nasal</i> | 13 | HOUR 450 MG ORAL..... | 7 |
| BAFIERTAM CAPSULE DELAYED RELEASE 95 | | GIMOTI SOLUTION 15 MG/ACT NASAL..... | 15 |
| MG ORAL..... | 21 | KESIMPTA SOLUTION AUTO-INJECTOR 20 | |
| BASAGLAR KWIKPEN SOLUTION PEN- | | MG/0.4ML SUBCUTANEOUS..... | 21 |
| INJECTOR 100 UNIT/ML SUBCUTANEOUS..... | 18 | LOFENA TABLET 25 MG ORAL..... | 8 |
| CAPLYTA CAPSULE 10.5 MG ORAL..... | 6 | LONHALA MAGNAIR REFILL KIT SOLUTION 25 | |
| CAPLYTA CAPSULE 21 MG ORAL..... | 6 | MCG/ML INHALATION..... | 19 |
| CAPLYTA CAPSULE 42 MG ORAL..... | 6 | LYBALVI TABLET 10-10 MG ORAL..... | 6 |
| <i>citalopram hydrobromide capsule 30 mg oral</i> | 10 | LYBALVI TABLET 15-10 MG ORAL..... | 6 |
| COPAXONE SOLUTION PREFILLED SYRINGE | | LYBALVI TABLET 20-10 MG ORAL..... | 6 |
| 20 MG/ML SUBCUTANEOUS..... | 21 | LYBALVI TABLET 5-10 MG ORAL..... | 6 |
| COPAXONE SOLUTION PREFILLED SYRINGE | | MAVENCLAD (10 TABS) TABLET THERAPY | |
| 40 MG/ML SUBCUTANEOUS..... | 21 | PACK 10 MG ORAL..... | 21 |
| CUPRIMINE CAPSULE 250 MG ORAL..... | 11 | MAVENCLAD (4 TABS) TABLET THERAPY | |
| DRIZALMA SPRINKLE CAPSULE DELAYED | | PACK 10 MG ORAL..... | 21 |
| RELEASE SPRINKLE 20 MG ORAL..... | 12 | MAVENCLAD (5 TABS) TABLET THERAPY | |
| DRIZALMA SPRINKLE CAPSULE DELAYED | | PACK 10 MG ORAL..... | 21 |
| RELEASE SPRINKLE 30 MG ORAL..... | 12 | MAVENCLAD (6 TABS) TABLET THERAPY | |
| DRIZALMA SPRINKLE CAPSULE DELAYED | | PACK 10 MG ORAL..... | 21 |
| RELEASE SPRINKLE 40 MG ORAL..... | 12 | MAVENCLAD (7 TABS) TABLET THERAPY | |
| DRIZALMA SPRINKLE CAPSULE DELAYED | | PACK 10 MG ORAL..... | 21 |
| RELEASE SPRINKLE 60 MG ORAL..... | 12 | MAVENCLAD (8 TABS) TABLET THERAPY | |
| ELYXYB SOLUTION 120 MG/4.8ML ORAL..... | 8 | PACK 10 MG ORAL..... | 21 |
| EPRONTIA SOLUTION 25 MG/ML ORAL..... | 14 | MAVENCLAD (9 TABS) TABLET THERAPY | |
| FANAPT TABLET 1 MG ORAL..... | 6 | PACK 10 MG ORAL..... | 21 |
| FANAPT TABLET 10 MG ORAL..... | 6 | MAYZENT STARTER PACK TABLET THERAPY | |
| FANAPT TABLET 12 MG ORAL..... | 6 | PACK 0.25 MG ORAL..... | 21 |
| FANAPT TABLET 2 MG ORAL..... | 6 | MAYZENT STARTER PACK TABLET THERAPY | |
| FANAPT TABLET 4 MG ORAL..... | 6 | PACK 12 X 0.25 MG ORAL..... | 21 |

| | | | |
|---|----|--|----|
| MAYZENT TABLET 0.25 MG ORAL..... | 21 | SAVELLA TITRATION PACK 12.5 & 25 & 50 | |
| MAYZENT TABLET 1 MG ORAL..... | 21 | MG ORAL..... | 27 |
| MAYZENT TABLET 2 MG ORAL..... | 21 | SECUADO PATCH 24 HOUR 3.8 MG/24HR | |
| NURTEC TABLET DISPERSIBLE 75 MG ORAL..... | 20 | TRANSDERMAL..... | 6 |
| <i>omeprazole-sodium bicarbonate packet 20-</i> | | SECUADO PATCH 24 HOUR 5.7 MG/24HR | |
| <i>1680 mg oral.....</i> | 24 | TRANSDERMAL..... | 6 |
| <i>omeprazole-sodium bicarbonate packet 40-</i> | | SECUADO PATCH 24 HOUR 7.6 MG/24HR | |
| <i>1680 mg oral.....</i> | 24 | TRANSDERMAL..... | 6 |
| ORTIKOS CAPSULE EXTENDED RELEASE 24 | | <i>sertraline hcl capsule 150 mg oral.....</i> | 28 |
| HOUR 6 MG ORAL..... | 9 | <i>sertraline hcl capsule 200 mg oral.....</i> | 28 |
| ORTIKOS CAPSULE EXTENDED RELEASE 24 | | TOSYMRA SOLUTION 10 MG/ACT NASAL..... | 20 |
| HOUR 9 MG ORAL..... | 9 | TRULANCE TABLET 3 MG ORAL..... | 29 |
| PONVORY STARTER PACK TABLET THERAPY | | UBRELVY TABLET 100 MG ORAL..... | 30 |
| PACK 2-3-4-5-6-7-8-9 & 10 MG ORAL..... | 21 | UBRELVY TABLET 50 MG ORAL..... | 30 |
| PONVORY TABLET 20 MG ORAL..... | 21 | <i>venlafaxine besylate er tablet extended release</i> | |
| PROAIR DIGIHALER AEROSOL POWDER | | <i>24 hour 112.5 mg oral.....</i> | 31 |
| BREATH ACTIVATED 108 (90 BASE) MCG/ACT | | VIIBRYD STARTER PACK KIT 10 & 20 MG | |
| INHALATION..... | 3 | ORAL..... | 32 |
| <i>rabeprazole sodium tablet delayed release 20</i> | | VIIBRYD TABLET 10 MG ORAL..... | 32 |
| <i>mg oral.....</i> | 24 | VIIBRYD TABLET 20 MG ORAL..... | 32 |
| RELAFEN DS TABLET 1000 MG ORAL..... | 8 | VIIBRYD TABLET 40 MG ORAL..... | 32 |
| RELISTOR SOLUTION 12 MG/0.6ML | | VRAYLAR CAPSULE 1.5 MG ORAL..... | 6 |
| SUBCUTANEOUS..... | 22 | VRAYLAR CAPSULE 3 MG ORAL..... | 6 |
| RELISTOR SOLUTION 8 MG/0.4ML | | VRAYLAR CAPSULE 4.5 MG ORAL..... | 6 |
| SUBCUTANEOUS..... | 22 | VRAYLAR CAPSULE 6 MG ORAL..... | 6 |
| RELISTOR TABLET 150 MG ORAL..... | 22 | VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 | |
| RELTONE CAPSULE 200 MG ORAL..... | 25 | MG ORAL..... | 6 |
| RELTONE CAPSULE 400 MG ORAL..... | 25 | VUMERITY CAPSULE DELAYED RELEASE 231 | |
| REXULTI TABLET 0.25 MG ORAL..... | 6 | MG ORAL..... | 21 |
| REXULTI TABLET 0.5 MG ORAL..... | 6 | WELLBUTRIN XL TABLET EXTENDED RELEASE | |
| REXULTI TABLET 1 MG ORAL..... | 6 | 24 HOUR 150 MG ORAL..... | 7 |
| REXULTI TABLET 2 MG ORAL..... | 6 | WELLBUTRIN XL TABLET EXTENDED RELEASE | |
| REXULTI TABLET 3 MG ORAL..... | 6 | 24 HOUR 300 MG ORAL..... | 7 |
| REXULTI TABLET 4 MG ORAL..... | 6 | XCOPRI (250 MG DAILY DOSE) TABLET | |
| RHOPRESSA SOLUTION 0.02 % OPHTHALMIC. | 23 | THERAPY PACK 100 & 150 MG ORAL..... | 33 |
| SANCUSO PATCH 3.1 MG/24HR | | XCOPRI (350 MG DAILY DOSE) TABLET | |
| TRANSDERMAL..... | 26 | THERAPY PACK 150 & 200 MG ORAL..... | 33 |
| SAPHRIS TABLET SUBLINGUAL 10 MG | | XCOPRI TABLET 100 MG ORAL..... | 33 |
| SUBLINGUAL..... | 6 | XCOPRI TABLET 150 MG ORAL..... | 33 |
| SAPHRIS TABLET SUBLINGUAL 2.5 MG | | XCOPRI TABLET 200 MG ORAL..... | 33 |
| SUBLINGUAL..... | 6 | XCOPRI TABLET 50 MG ORAL..... | 33 |
| SAPHRIS TABLET SUBLINGUAL 5 MG | | XCOPRI TABLET THERAPY PACK 14 X 12.5 | |
| SUBLINGUAL..... | 6 | MG & 14 X 25 MG ORAL..... | 33 |
| SAVELLA TABLET 100 MG ORAL..... | 27 | XCOPRI TABLET THERAPY PACK 14 X 150 MG | |
| SAVELLA TABLET 12.5 MG ORAL..... | 27 | & 14 X200 MG ORAL..... | 33 |
| SAVELLA TABLET 25 MG ORAL..... | 27 | XCOPRI TABLET THERAPY PACK 14 X 50 MG | |
| SAVELLA TABLET 50 MG ORAL..... | 27 | & 14 X100 MG ORAL..... | 33 |

| | |
|---|----|
| ZEPOSIA 7-DAY STARTER PACK CAPSULE THERAPY PACK 4 X 0.23MG & 3 X 0.46MG ORAL..... | 21 |
| ZEPOSIA CAPSULE 0.92 MG ORAL..... | 21 |
| ZEPOSIA STARTER KIT CAPSULE THERAPY PACK 0.23MG & 0.46MG & 0.92MG ORAL..... | 21 |